Clofibrate, a fibric acid derivative, is a selective agonist of peroxisome proliferator-activated receptor α (PPARα) with EC50 of 50 µM. Clofibrate has been used to treat hyperlipoproteinemia type III and severe hypertriglyceridemia.
Clofibrate, a fibric acid derivative, is a selective agonist of PPARα with EC50 of 50 µM. Clofibrate has been used to treat hyperlipoproteinemia type III and severe hypertriglyceridemia[3]. Clofibrate (0.5, 1, 2 mM) increases FABP1 expression in two fatty acid (FA)-treated rat hepatoma cells. Clofibrate lowers ROS levels after early treatment, much more than late treatment in FA-treated cells[4]. Moreover, clofibrate administration to 7 days MI-rats exerts an antioxidant, pro-vasodilator expression profile, and anti-fibrotic effect suggesting that PPARα activation can be considered a therapeutic target to improve cardiac condition posterior to ischemia[5]. Giving CF (0.5% Clofibrate) to pregnant mice programmed greater HFD(high-fat diet)-induced WAT (white adipose tissue) browning in subcutaneous, but not in visceral fat, in their male offspring at adulthood[6].
Prostate Cancer
... 展开 >> Metabolic Syndrome 收起 <<
Phase 3
Not yet recruiting
June 1, 2023
Canada, British Columbia
... 展开 >>
BC Cancer Agency - Vancouver Cancer Centre
Not yet recruiting
Vancouver, British Columbia, Canada, V5Z 4E6
Contact: Bernie Eigl, MD 604-877-6000 bernie.eigl@bccancer.bc.ca
Principal Investigator: Bernie Eigl, MD 收起 <<
Prostate Cancer
... 展开 >> Metabolic Syndrome 收起 <<
Phase 3
Not yet recruiting
June 1, 2023
Canada, British Columbia
... 展开 >>
BC Cancer Agency - Vancouver Cancer Centre
Not yet recruiting
Vancouver, British Columbia, Canada, V5Z 4E6
Contact: Bernie Eigl, MD 604-877-6000 bernie.eigl@bccancer.bc.ca
Principal Investigator: Bernie Eigl, MD 收起 <<
搜索
